World news story

Collaboration is cure for better global health outcomes

Leaders in healthcare meet to discuss ways to boost improvements in medicine manufacturing.

BDHC Bengaluru

Healthcare and biotechnology companies should be focused on developing blockbuster drugs that benefit billions of patients, says world-leading healthcare experts, and this can only be done through collaboration and innovation they say.

Speaking at the opening day of the Bangalore India Bio, leaders in life sciences presented their views at the UK Trade & Investment (UKTI) India Making Tomorrows Medicine.

Speaking at the event, Indian entrepreneur and chairwoman of India’s biggest bio-tech company, Biocon Limited, Dr Kiran Mazumdar Shaw, said in making the Medicines of Tomorrow, the endeavour should be to leverage innovation to develop therapies which are affordable and accessible.

Shaw said:

As global priorities shift from providing exclusive and expensive drugs to more affordable drugs to enhance access to greater patient populations, we need to focus on developing blockbuster drugs with a potential to benefit a billion patients,

A developing country like India, needs to invest in an affordable innovation model that can help address the burgeoning healthcare challenges of India, where 80 percent of healthcare expenses are borne by the patients, in the absence of a universal healthcare program run by the government.

She added:

The UK, with its ecosystem of research institutes, innovative companies and a large scientific pool, has become an important destination for high-end innovation and research. As large numbers of Indian companies commit themselves to innovation, UK’s innovation ecosystem can provide learning opportunities for these companies to develop new competencies through collaborative research and alliances and join hands in their pursuit of addressing unmet medical needs.

The UK has the strongest overseas presence with more than 20 companies participating in the 16th edition of Bangalore India Bio. The British Deputy High Commissioner, Dominic McAllister, said the UK and India have built a legacy of collaboration in life sciences over recent years.

He said:

Our role within the British Deputy High Commission in Bengaluru is to not only strengthen existing links, but also to explore new ways of working together. Making Tomorrow’s Medicines in India using UK capabilities is aligned to Prime Minister Modi’s vision of Make In India and is an example of GREAT for Collaboration an exciting campaign that inspires new partnerships between the UK and India.

The UK has a long track record of cost-effective and compliant medicines manufacturing from leading global companies. India has taken over from Italy as one of the leading supplier of manufacturing supply chains and is ideally positioned to be the hub of activity around Making Tomorrow’s Medicine.

Jon Mowles, UKTI Life Science Sector Specialist, who is leading the British delegation, said that the UK has a rich heritage of life science discovery that has transformed scientific knowledge and continues to unlock clinical and commercial opportunities.

He said:

UK science is world-class, offering industry an opportunity to partner with globally recognised pioneers and innovators. Approximately twenty five percent of all drugs prescribed in the UK have an Indian origin and I am looking forward to meeting Indian experts and to discuss how we can Make Tomorrow’s Medicine together.

Interested parties can also visit and meet UKTI investment advisors at Bangalore Bio 2016 who can assist with collaboration opportunities with the UK.

Further information:

UKTI participation in Bangalore India Bio 2016

  • Making Tomorrow’s Medicine (MTM): UK Trade and Investment along with other UK government departments in their headquarters are working on a global campaign on supporting select countries in Making Tomorrow’s Medicine that the world will need. This could be towards technology transfer for global vaccine design and development or process innovations towards sustainability in fuels in the pharma manufacturing industry. The UK has strengths in most. This also sits very well with the ‘Make in India’ campaign.

  • Indo UK knowledge series for start ups

  • view photos of Bangalore India Bio 2016 here.

GREAT for Collaboration

GREAT for Collaboration is an ambitious and exciting new campaign to showcase India-UK business collaboration. The campaign, launched by Prime Minister Modi and Prime Minister Cameron, will inspire new partnerships and encourage greater awareness of the scale of the UK’s commitment to India. The overall objective is to increase business between the two countries. The campaign showcases and promotes collaborations of mutual benefit to India and the UK across a range of sectors, such as energy, healthcare, advanced manufacturing, financial services and infrastructure.

GREAT for Collaboration video

GREAT for Collaboration video

Find out why the UK is the most attractive overseas business destination.

Find out why the UK is the most attractive overseas business destination

For more information or interviews with Deputy High Commissioner, Dominic McAllister or Jon Mowles, UKTI Life Science Sector Specialist, please email:

For media queries, please contact:

Stuart Adam, Head,
Press and Communications
British High Commission, Chanakyapuri
New Delhi 110021
Tel: 44192100; Fax: 24192411

Mail to: Jagori Dhar

Follow us on Twitter, Facebook, Flickr, Storify, Eventbrite, Blogs, Foursquare, Youtube, Instagram, Vine, Snapchat @UKinIndia, Periscope @UKinIndia

Published 9 February 2016
Last updated 10 February 2016 + show all updates
  1. Added translation
  2. First published.